Summary: Zevra Therapeutics announced that Rene Braeckman, PhD, the company’s senior vice president of clinical development, will present top-line data from the phase 2 clinical trial of KP1077 (serdexmethylphenidate) in patients with idiopathic hypersomnia (IH) at Sleep Europe … [Read more...]
Zevra’s KP1077 Progresses With Positive Phase 2 Data in IH
Summary: In Q1 2024, Zevra Therapeutics claimed constructive topline info from its section 2 research of KP1077 in idiopathic hypersomnia, demonstrating promising tolerance and early indicators of significant advantages. The complete results will be offered at Snooze 2024, and an … [Read more...]
Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP
Summary: At Slumber 2024, Zevra Therapeutics will existing the whole information from the KP1077 section 2 trial for idiopathic hypersomnia, signaling potential progress into stage 3 trials. A shareholder letter from CEO Neil McFarlane underscores this milestone, alongside … [Read more...]